Skip to main content
GRML
NASDAQ Life Sciences

CFO LeBlanc Buys $136K of Greenland Mines Stock at $9.72

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$9.24
Mkt Cap
$29.356M
52W Low
$7.815
52W High
$39.45
52W Position info
18% above low
Off High info
77% below high
Rel. Volume info
6.8× avg
Market data snapshot near publication time

GRML sits 18% above its 52-week low of $7.815 on elevated volume (6.8× avg).

Summary

CFO Jeff LeBlanc bought $136,080 of Greenland Mines stock at $9.72 per share, increasing his direct holdings to 110,406 shares.


Key Events · Ownership and Investor Activity · GRML

  • CFO Buys $136K of Stock

    Jeff LeBlanc purchased 14,000 shares at $9.72 per share for $136,080 on August 25, 2026.

  • Stake Rises to 110,406 Shares

    Post-transaction direct holdings total 110,406 shares, following a prior 1.4 million share purchase on July 17 at $0.1752 (pre-split).

  • Second Purchase in Five Weeks

    This is LeBlanc's second open-market buy since July 17, 2026, signaling continued insider accumulation.

  • Post-Reverse-Split Timing

    The purchase occurred one day after the 1-for-50 reverse split took effect on August 24, 2026.


Analysis · GRML · Life Sciences

CFO Jeff LeBlanc bought 14,000 shares for $136,080 at $9.72 on August 25, 2026, lifting his direct stake to 110,406 shares. This is his second open-market purchase in five weeks — he bought 1.4 million shares for $245,280 at $0.1752 on July 17, before the 1-for-50 reverse split. The new purchase comes one day after the reverse split took effect and on the same day the company released a maiden S-K 1300 Initial Assessment for its Sarfartoq rare earth project. Against a backdrop of going-concern doubts and a Nasdaq delisting deadline, the CFO putting fresh cash to work is a meaningful insider conviction signal.

How filings like this one have moved

In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GRML was trading at $9.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.4M. The 52-week trading range was $7.82 to $39.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRML - Latest Insights

GRML
Aug 25, 2026, 12:01 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.64
Real-time Price: $9.85 info
Change: +$1.21 (+14%) info
Market Cap: $31.287M info
GRML
Aug 24, 2026, 5:01 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $8.36
Real-time Price: $9.85 info
Change: Reverse Stock Split info
Market Cap: $31.287M info
GRML
Aug 24, 2026, 10:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.99
Real-time Price: $9.85 info
Change: Reverse Stock Split info
Market Cap: $31.287M info
GRML
Aug 20, 2026, 9:25 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1762
Real-time Price: $9.85 info
Change: Reverse Stock Split info
Market Cap: $31.287M info
GRML
Aug 17, 2026, 5:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1978
Real-time Price: $9.85 info
Change: Reverse Stock Split info
Market Cap: $31.287M info